Pharmacotherapeutic effect of quercetin delivery systems in experimental acute respiratory distress syndrome induced by acid aspiration
DOI:
https://doi.org/10.14739/mmt.2025.4.340570Keywords:
quercetin, aspiration, acute respiratory distress syndrome, liposomesAbstract
Predictive justification and experimental confirmation of the pharmacotherapeutic effect of quercetin incorporated into the phosphatidylcholine liposomes or the povidone matrix in a model of acute respiratory distress syndrome induced by intratracheal aspiration of hydrochloric acid are presented.
Aim. To establish the phenomenon of the pharmacotherapeutic action of quercetin in transport systems in acute respiratory distress syndrome caused by acid aspiration, using various methods of administration in order to provide experimental justification for the broader clinical translation of known quercetin formulations.
Materials and methods. The study was conducted in compliance with bioethical standards using Balb/c mice (25–30 g, both sexes) from the vivarium of the State Institution “Institute of Pharmacology and Toxicology of the National Academy of Medical Sciences of Ukraine”. Acute respiratory distress syndrome (ARDS) was modeled by intratracheal instillation of 0.1 N HCl after propofol anesthesia. Control animals received sterile saline. Two drugs were studied: Lipoflavon® (liposomal quercetin formulation) and Corvitin® (water-soluble quercetin derivative). The samples were administered intravenously and/or by inhalation according to different regimens for 5 days. Therapeutic efficacy was assessed by survival, body weight dynamics, clinical status, and histological examination of lungs and heart. Tissue samples were fixed in formalin, paraffin-embedded, sectioned, stained with hematoxylin-eosin, and examined by light microscopy. Statistical analysis was performed using the Shapiro–Wilk normality test, one-way analysis of variance (ANOVA), or Kruskal–Wallis criterion (p ≤ 0.05). The analysis was performed in Microsoft Excel and using the Statistics Kingdom online calculator.
Results. The phenomenon of the therapeutic and prophylactic effect of the studied quercetin transport systems (drugs Lipoflavon and Corvitin) was established in terms of their protective effect on the dynamics of survival (growth up to 100 %), normalization of the clinical condition and weight of animals during ARDS induction by acid aspiration. The pharmacotherapeutic effect of inhalation and injection administration of the studied quercetin preparations was visualized by the histo-morphological picture of structural restoration and anti-inflammatory process in the target lungs and bronchi, which are deeply affected in the ARDS model.
Conclusions. The obtained experimental results should contribute to the justification of the clinical translation of drugs based on quercetin transport systems in the medical technology of ARDS treatment.
References
Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. Lancet. 2021;398(10300):622-37. doi: https://doi.org/10.1016/S0140-6736(21)00439-6
Ma W, Tang S, Yao P, Zhou T, Niu Q, Liu P, et al. Advances in acute respiratory distress syndrome: focusing on heterogeneity, pathophysiology, and therapeutic strategies. Signal Transduct Target Ther. 2025;10(1):75. doi: https://doi.org/10.1038/s41392-025-02127-9
Lee CT, Gandhi SA, Elmrayed S, Barnes H, Lorenzetti D, Salisbury ML, et al. Inhalational exposures associated with risk of interstitial lung disease: a systematic review and meta-analysis. Thorax. 2025;80(12):918-26. doi: https://doi.org/10.1136/thorax-2024-222306
Empson S, Rogers AJ, Wilson JG. COVID-19 Acute Respiratory Distress Syndrome: One Pathogen, Multiple Phenotypes. Crit Care Clin. 2022;38(3):505-19. doi: https://doi.org/10.1016/j.ccc.2022.02.001
Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020;53(3):404-12. doi: https://doi.org/10.1016/j.jmii.2020.02.012
Md Idris MH, Mohd Amin SN, Mohd Amin SN, Nyokat N, Khong HY, Selvaraj M, et al. Flavonoids as dual inhibitors of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and in vitro studies. Beni-Suef Univ J Basic Appl Sci. 2022;11:117. doi: https://doi.org/10.1186/s43088-022-00296-y
Al-Khayri JM, Sahana GR, Nagella P, Joseph BV, Alessa FM, Al-Mssallem MQ. Flavonoids as Potential Anti-Inflammatory Molecules: A Review. Molecules. 2022;27(9):2901. doi: https://doi.org/10.3390/molecules27092901
Chen S, Wang X, Cheng Y, Gao H, Chen X. A Review of Classification, Biosynthesis, Biological Activities and Potential Applications of Flavonoids. Molecules. 2023;28(13):4982. doi: https://doi.org/10.3390/molecules28134982
Frenț OD, Stefan L, Morgovan CM, Duteanu N, Dejeu IL, Marian E, et al. A Systematic Review: Quercetin-Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability. Int J Mol Sci. 2024;25(22):12091. doi: https://doi.org/10.3390/ijms252212091
Arber Raviv S, Alyan M, Egorov E, Zano A, Harush MY, Pieters C, et al. Lung targeted liposomes for treating ARDS. J Control Release. 2022;346:421-33. doi: https://doi.org/10.1016/j.jconrel.2022.03.028
Yu Y, Qiu L. Nanotherapy therapy for acute respiratory distress syndrome: a review. Front Med (Lausanne). 2024;11:1492007. doi: https://doi.org/10.3389/fmed.2024.1492007
Jiang P, Jin Y, Sun M, Jiang X, Yang J, Lv X, et al. Extracellular histones aggravate inflammation in ARDS by promoting alveolar macrophage pyroptosis. Mol Immunol. 2021;135:53-61. doi: https://doi.org/10.1016/j.molimm.2021.04.002
Zhang K, Ren X, Chen J, Wang C, He S, Chen X, et al. Particle Design and Inhalation Delivery of Iodine for Upper Respiratory Tract Infection Therapy. AAPS PharmSciTech. 2022;23(6):189. doi: https://doi.org/10.1208/s12249-022-02277-x
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 N. V. Stepanova, Z. S. Suvorova, O. Ye. Yadlovskyi, G. S. Grygorieva, N. F. Konakhovych
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The work is provided under the terms of the Public Offer and of Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows an unlimited number of persons to reproduce and share the Licensed Material in all media and formats. Any use of the Licensed Material shall contain an identification of its Creator(s) and must be for non-commercial purposes only.
